CN110585280A - Pharmaceutical composition for treating acne - Google Patents
Pharmaceutical composition for treating acne Download PDFInfo
- Publication number
- CN110585280A CN110585280A CN201910857777.2A CN201910857777A CN110585280A CN 110585280 A CN110585280 A CN 110585280A CN 201910857777 A CN201910857777 A CN 201910857777A CN 110585280 A CN110585280 A CN 110585280A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- parts
- bacteria
- acne
- oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical composition for treating acne comprises the following raw materials in parts by mass: 0.1-2 parts of galacto-oligosaccharide, 0.1-2 parts of isomalto-oligosaccharide, 0.1-2 parts of acerola powder, 0.1-2 parts of yeast zinc, 0.1-2 parts of yeast glucan and a proper amount of mixed bacteria, wherein the mixed bacteria comprise lactobacillus fermentum, lactobacillus paracasei, lactobacillus rhamnosus, lactobacillus acidophilus and lactobacillus plantarum. The invention treats bacteria by bacteria, gradually reduces the propagation of harmful bacteria by the expanded growth of active probiotics, avoids the continuous infection of the harmful bacteria, improves the inflammation, can treat acne and simultaneously improve the immunity of human bodies, has short treatment course, obvious curative effect, safety and no toxicity, and has good popularization and application prospect.
Description
Technical Field
The invention particularly relates to a pharmaceutical composition for treating acne.
Background
Acne is a chronic inflammatory skin disease of the pilosebaceous unit, is characterized by polymorphic skin lesions such as comedo, papule, pustule, nodule and the like which are better developed on the face in clinical manifestation, is a multifactorial disease, and is closely related to factors such as sex hormone level, massive secretion of sebaceous glands, proliferation of propionibacterium acnes, abnormal keratinization of pilosebaceous ducts, inflammation and the like. In the prior art, the treatment of acne mainly comprises the following steps: firstly, western medicine treatment is carried out, western medicine generally carries out treatment according to acne grades, mild acne generally adopts tretinoin cream or gel, benzoyl peroxide gel can kill propionibacterium acnes and has no drug resistance, moderate acne needs to be matched with oral antibiotics, and severe acne needs to be orally taken isotretinoin; secondly, hormone therapy is mainly aimed at people with severe facial acne, the hormone therapy is required to be strictly carried out under the guidance of doctors, and hormone dermatitis can be caused by self-misuse and abuse; thirdly, the traditional Chinese medicine treatment has long treatment course and is easy to cause unstable curative effect due to large individual difference; fourthly, the photodynamic local treatment has no side effect on the whole body, achieves the aims of preventing relapse and formation of pox scars, pockmarks and scars, but has high price.
Apparently, conventional acne treatments seem simple and act with drugs that kill acne-associated bacteria with a significant short duration, but due to the broad spectrum of most prescribed antibiotics, the result of the "shotgun" may be a large kill of commensal beneficial bacteria, thus destroying the beneficial bacterial membrane on the skin surface, causing a large number of harmful bacteria to more easily invade the skin, thus contributing to the potential for further hormonal imbalance, which in turn is likely to trigger the recurrence of acne, resulting in the vicious circle. Therefore, the development of the acne treatment method which has short treatment course, long-term stable curative effect and no damage to human safety is of great practical significance.
Disclosure of Invention
The technical problem to be solved by the invention is to provide the pharmaceutical composition for treating the acne, which has short treatment course, obvious curative effect and no harm to human body.
The technical problem solved by the invention is realized by adopting the following technical scheme:
a pharmaceutical composition for treating acne comprises the following raw materials in parts by mass: 0.1-2 parts of galacto-oligosaccharide, 0.1-2 parts of isomalto-oligosaccharide, 0.1-2 parts of acerola powder, 0.1-2 parts of yeast zinc, 0.1-2 parts of yeast glucan and a proper amount of mixed bacteria, wherein the mixed bacteria comprise lactobacillus fermentum, lactobacillus paracasei, lactobacillus rhamnosus, lactobacillus acidophilus and lactobacillus plantarum.
Preferably, the feed comprises the following raw materials in parts by mass: 1 part of galacto-oligosaccharide, 1 part of isomalto-oligosaccharide, 1 part of acerola powder, 1 part of yeast zinc, 1 part of yeast glucan and a proper amount of mixed bacteria.
Preferably, the number of viable bacteria of the mixed bacteria per gram of galactooligosaccharide is 120-300 hundred million.
Preferably, the ratio of the number of the viable bacteria of the lactobacillus fermentum, the lactobacillus paracasei, the lactobacillus rhamnosus, the lactobacillus acidophilus and the lactobacillus plantarum is 1:2:1:1: 1.
The galacto-oligosaccharide is a low molecular weight water-soluble dietary fiber, has fresh and cool taste and lower calorific value, is the only oligosaccharide which can be utilized by various probiotics in human intestines, and the harmful flora can not be utilized.
Isomaltooligosaccharide: isomaltooligosaccharide belongs to indigestible sugar, is not easy to be digested and absorbed by stomach and small intestine of a human body and directly enters large intestine, and is preferentially utilized by beneficial bacteria such as bifidobacterium and the like, harmful bacteria such as escherichia coli, salmonella and the like cannot be utilized, the isomaltooligosaccharide generates a large amount of acids and some antibacterial substances, can inhibit the propagation of harmful bacteria and exogenous pathogenic bacteria in intestinal tract, can restore normal flora of intestinal tract of a person with microecological disorder, and promotes intestinal tract microorganisms to be adjusted in a good direction, so that the isomaltooligosaccharide has a very key effect on adjusting a digestive tract microflora and promoting the rapid propagation of the beneficial flora;
acerola cherry: the vitamin C content of the currently planted plants is the third highest, the vitamin C content in every 100g of fruits reaches 1677 mg, the vitamin C content is only next to Kadu plum and kamu fruit, is 31 times of lemon, 27 times of strawberry and 18 times of kiwi fruit, and is also 7 times of guava considered to be extremely high in vitamin C, so that the vitamin C is one of 'the king of natural vitamin C' which is worthy of the name, and simultaneously contains elements such as vitamin A, vitamin B1, vitamin B2, iron, calcium and the like, the vitamin C is an important component which can not be deficient in maintaining human life, and has an important effect on improving the resistance of human body;
yeast zinc: is a representative of biological zinc belonging to the third generation, and the zinc is absorbed and converted by yeast in the growth process, and is combined with yeast protein and polysaccharide to form pure biological zinc, so that an adequate carrier is provided for the absorption of the zinc, the bioavailability is up to more than 70 percent, and the acne recurrence caused by the lack of zinc element and malnutrition can be prevented;
yeast glucan: the natural yeast glucan has unique targeting effect, can directionally remove vivotoxin, and simultaneously improves the phagocytic capacity of macrophages by more than 10 times, so that the immune system of a human body quickly reaches the optimal balance without any toxic or side effect of medicines;
lactobacillus fermentum: the human lactobacillus ferments can also effectively stimulate the secretion of gamma-interferon so as to have certain antiallergic effect on dermatitis.
Lactobacillus paracasei 3 has a certain improvement effect on atopic dermatitis.
Lactobacillus rhamnosus: the lactobacillus rhamnosus can tolerate the animal digestive tract environment, can be planted in the intestinal tracts of human beings and animals, has the effects of regulating intestinal flora, preventing and treating diarrhea, removing toxins, improving the immunity of organisms and the like, and has a good relieving effect on allergic constitution.
Lactobacillus acidophilus: regulating intestinal flora balance, inhibiting proliferation of intestinal undesirable microorganisms, and promoting health.
Lactobacillus plantarum: has certain immunoregulation effect, has pathogenic bacteria inhibiting effect, maintains intestinal flora balance, and promotes nutrient absorption.
The principle of the invention is as follows: the species of bacteria on human skin is between 500 and 1000, the number of bacteria is hundreds of millions, and most of the bacteria are harmless or even beneficial, and contrary to the conventional concept of acne treatment, the present invention ensures that probiotics thrive as a basis for treating acne by maximizing the growth of beneficial bacteria rather than destroying harmful bacteria. Since most acne patients have unbalanced flora on their skin surface, while the probiotics of the present invention promote the balance of bacterial flora in the digestive tract and on the body surface, thus helping to control acne, the probiotics inhibit the growth of harmful bacteria on the skin and thus have a significant effect on reducing sebum secretion and inflammation.
The beneficial bacteria formula of the invention is extremely important, which determines whether the flora can be fully absorbed by the human body after entering the human body, and has good inhibition effect on acne inflammation while adjusting the balance of the flora of the human body, and the precise proportion of the preferable natural VC (acerola cherry) powder, the yeast zinc, the yeast glucan, the galactooligosaccharide and the isomaltooligosaccharide is also important, which determines whether the beneficial bacteria flora can grow to a certain degree, so that the flora of the human body can not be disturbed due to overgrowth or can not reach the standard due to growth.
Has the advantages that: 1) the invention has unique formula, safety and no toxicity, and has good regulation effect on the human body resistance on the basis of obvious curative effect on acne;
2) the raw material components of the invention are scientifically and reasonably matched, the acerola, the yeast zinc, the yeast glucan, the galacto-oligosaccharide and the isomalto-oligosaccharide ensure and promote the proper growth of beneficial flora and can fully play a role after entering human body, and the selection and matching of the species of the probiotics ensure that the acne is fully inhibited and cured from different angles of human body requirements and play a very important role in regulating the health of the human body.
Detailed Description
In order to make the technical means, the creation characteristics, the achievement purposes and the effects of the invention easy to understand, the invention is further described with the specific embodiments.
Example 1
The preparation method comprises the steps of uniformly mixing 200g of galactooligosaccharide, 150g of isomaltooligosaccharide, 120g of acerola powder, 200g of yeast zinc, 200g of yeast glucan, 2000 hundred million strains of lactobacillus fermentum, 4000 million strains of lactobacillus paracasei, 2000 million strains of lactobacillus rhamnosus, 2000 million strains of lactobacillus acidophilus and 2000 million strains of lactobacillus plantarum to obtain powder, and sealing and packaging the powder.
Example 2
100g of galacto-oligosaccharide, 100g of isomaltooligosaccharide, 100g of acerola powder, 100g of yeast zinc, 100g of yeast glucan, 5000 hundred million strains of lactobacillus fermentum, 10000 million strains of lactobacillus paracasei, 5000 million strains of lactobacillus rhamnosus, 5000 million strains of lactobacillus acidophilus and 5000 million strains of lactobacillus plantarum are taken, uniformly mixed to obtain powder, and the powder is sealed and packaged.
Example 3
Taking 10g of galacto-oligosaccharide, 15g of isomalto-oligosaccharide, 18g of acerola powder, 20g of yeast zinc, 15g of yeast glucan, 300 hundred million strains of lactobacillus fermentum, 600 million strains of lactobacillus paracasei, 300 million strains of lactobacillus rhamnosus, 300 million strains of lactobacillus acidophilus and 300 million strains of lactobacillus plantarum, uniformly mixing to obtain powder, and sealing and packaging.
In examples 1 to 3, Lactobacillus fermentum, Lactobacillus paracasei and Lactobacillus plantarum were purchased from Biotechnology (Nanjing) Ltd, and Lactobacillus rhamnosus and Lactobacillus acidophilus were purchased from Dupont Danisco, USA.
The composition described in example 2 was found to have the best clinical performance during the experiment.
Statistically, the composition described in example 2 was administered to a patient in a total of 105 patients in clinical trials, 2 times a day at 4g each time, and 1 month as a treatment course.
The statistical results are as follows: the total number of the patients is 105, 95 cases are cured, 6 cases are effective, 4 patients have unobvious effect, the effective rate is as high as 96.2%, 2.4 treatment courses are averagely needed in cured patients, and the number of acne recurrence is only 5 and the recurrence rate is 5.2% in one year after cure.
In conclusion, the medicament disclosed by the invention is short in treatment course of acne, remarkable in curative effect, free of any adverse reaction in the treatment process and safe in medication.
Some of the cases of this composition during the trial are published as follows:
case one
The adult girl plums work in foreign enterprises, the acne on the face is more than ten years old at 25 years old, the acne starts growing on the face in the early middle and early years, and the acne cannot be picked up later and is not stopped all the time. The whole face is pimple and red, so the face never feels no good at a low stage, never dares to look at a mirror, and always gets low at a place with many people. Various acne removing products are continuously tried, but the acne removing products are not successful finally, the composition is taken in the last 3 months, after four continuous treatment courses, the acne disappears but the pores are relatively large, after four continuous treatment courses, the acne does not relapse, and the pores become fine and smooth until no relapse occurs.
Case two
Miss aged, age 27, company staff, after three courses of administration of the composition product, face acne had been substantially eliminated, acne marks were also improved, and no recurrence was observed.
Case three
Remiansheng, 25 years old and IT elite, a plurality of acne removing methods are tried, the effect is not good, and after the composition product is taken for 1.5 treatment courses, the acne on the face is completely eliminated, and then the acne does not relapse.
Case four
Wu-lady, 36 years old, housewives, plagued pox for many years, and became more serious after the child was born. Many treatments have been done in beauty salons and acne has been more devastating without any effect. After the composition product is taken for 3.5 treatment courses, obvious acnes are basically not seen, pigmentation is slowly relieved and then relapses, and the acnes are healed after the composition product is continuously taken for one treatment course until now.
The foregoing shows and describes the general principles, essential features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (4)
1. The pharmaceutical composition for treating acne is characterized by comprising the following raw materials in parts by mass: 0.1-2 parts of galacto-oligosaccharide, 0.1-2 parts of isomalto-oligosaccharide, 0.1-2 parts of acerola powder, 0.1-2 parts of yeast zinc, 0.1-2 parts of yeast glucan and a proper amount of mixed bacteria, wherein the mixed bacteria comprise lactobacillus fermentum, lactobacillus paracasei, lactobacillus rhamnosus, lactobacillus acidophilus and lactobacillus plantarum.
2. The pharmaceutical composition for the treatment of acne according to claim 1, characterized by comprising the following raw materials in parts by mass: 1 part of galacto-oligosaccharide, 1 part of isomalto-oligosaccharide, 1 part of acerola powder, 1 part of yeast zinc, 1 part of yeast glucan and a proper amount of mixed bacteria.
3. The pharmaceutical composition for treating acne according to any of claims 1-2, wherein the number of viable bacteria of mixed bacteria per gram of galacto-oligosaccharide is 120-300 hundred million.
4. The pharmaceutical composition for the treatment of acne according to claim 3, characterized in that the ratio of the number of viable bacteria of Lactobacillus fermentum, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus and Lactobacillus plantarum is 1:2:1:1: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910857777.2A CN110585280A (en) | 2019-09-09 | 2019-09-09 | Pharmaceutical composition for treating acne |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910857777.2A CN110585280A (en) | 2019-09-09 | 2019-09-09 | Pharmaceutical composition for treating acne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110585280A true CN110585280A (en) | 2019-12-20 |
Family
ID=68858859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910857777.2A Pending CN110585280A (en) | 2019-09-09 | 2019-09-09 | Pharmaceutical composition for treating acne |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110585280A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114788795A (en) * | 2021-11-15 | 2022-07-26 | 广州极男化妆品有限公司 | Acne-removing composition and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111513224A (en) * | 2020-04-26 | 2020-08-11 | 湖南益优健康产业有限公司 | Solid beverage suitable for endurance exercise |
-
2019
- 2019-09-09 CN CN201910857777.2A patent/CN110585280A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111513224A (en) * | 2020-04-26 | 2020-08-11 | 湖南益优健康产业有限公司 | Solid beverage suitable for endurance exercise |
Non-Patent Citations (1)
| Title |
|---|
| 无: "脸上起痘痘怎么办一个百试百灵的有效祛痘秘方", 《HTTP://WWW.51SOLE.COM/B2B/SIDES30211685.HTML》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114788795A (en) * | 2021-11-15 | 2022-07-26 | 广州极男化妆品有限公司 | Acne-removing composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1604677A1 (en) | Composition having antioxidant, anti-inflammatory, and immunostimulant actions | |
| US20070286916A1 (en) | Synbiotic Use | |
| CN109464487A (en) | Probiotics compound of anti-helicobacter pylori and preparation method thereof | |
| CN113925923B (en) | Anti-acne and whitening compound probiotic composition and preparation method thereof | |
| CN111956671A (en) | Composite probiotics for treating helicobacter pylori infection | |
| WO2021135798A1 (en) | Application of mulberroside a and derivatives thereof in preparation of drugs for protecting intestinal barrier | |
| US10369184B2 (en) | Composition and use thereof in manufacture of product for improving intestinal function | |
| CN103750324A (en) | Milk basic protein hericium erinaceus powder composite piece | |
| WO2005030230A1 (en) | Compositions and methods for treatment or prevention of psoriasis and related disorders | |
| CN114931598A (en) | Gastric soluble sustained-release tablet for preventing and treating helicobacter pylori infection and preparation method thereof | |
| CN110585280A (en) | Pharmaceutical composition for treating acne | |
| CN107319550A (en) | Brain trauma full nutrition formula food | |
| CN111374896A (en) | Prebiotics and probiotic skin care product for treating acne and preparation method thereof | |
| CN108782963A (en) | It is a kind of can antibacterial improve immunity probiotics and preparation method thereof | |
| CN114767728B (en) | Composition for preventing and treating Parkinson's disease and preparation method thereof | |
| CN115486541B (en) | Herbal probiotic composition with whitening effect and preparation method thereof | |
| CN111166776A (en) | Formula for eradicating chronic gastritis caused by helicobacter pylori | |
| CN110050972B (en) | Aloe and hawthorn ball and preparation method thereof | |
| CN113384662A (en) | Helicobacter pylori-resistant probiotic composition and preparation method and application thereof | |
| KR101695488B1 (en) | Composition for preventing and improving of diarrohea, and oral syringe package using the same | |
| CN107050106A (en) | A kind of lozenge for being used to prevent and treat chronic pharyngitis | |
| CN108969648B (en) | Pharmaceutical composition and application method thereof | |
| RU2394567C1 (en) | Method of treating chronic pharyngitis with novocaine and mexidol solution | |
| WO2020252545A1 (en) | Nutraceutical composition combining probiotics, vitamins and minerals | |
| KR102606636B1 (en) | Bacillus velezensis having the effect of preventing or improving for sarcopenia and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191220 |
|
| RJ01 | Rejection of invention patent application after publication |